Citigroup Inc Mereo Biopharma Group PLC Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.71 - $1.22 $801,663 - $1.38 Million	1,129,103 Added 72986.62%	1,130,650 $802,000
Q4 2022 Feb 09, 2023	SELL	$0.5 - $1.01 $8,684 - $17,541	-17,368 Reduced 91.82%	1,547 $1,000
Q3 2022 Nov 10, 2022	BUY	$0.82 - $1.73 $13,976 - $29,486	17,044 Added 910.96%	18,915 $16,000
Q2 2022 Aug 10, 2022	SELL	$0.33 - $1.69 $213 - $1,093	-647 Reduced 25.69%	1,871 $2,000
Q1 2022 May 12, 2022	SELL	$1.04 - $1.7 $891 - $1,456	-857 Reduced 25.39%	2,518 $3,000
Q4 2021 Feb 10, 2022	BUY	$1.51 - $2.59 $5,096 - $8,741	3,375 New	3,375 $5,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.